Overcoming barriers in HPV vaccination and screening programs

dc.contributor.authorVorsters, Alex
dc.contributor.authorVan Damme, Pierre
dc.contributor.authorArbyn, Marc
dc.contributor.authorBaay, Marc
dc.contributor.authorBosch José, Francesc Xavier, 1947-
dc.contributor.authorSanjosé Llongueras, Silvia de
dc.contributor.authorHanley, Sharon
dc.contributor.authorKarafillakis, Emilie
dc.contributor.authorLopalco, Pier Luigi
dc.contributor.authorPollock, Kevin G.
dc.contributor.authorYarwood, Joanne
dc.date.accessioned2018-07-27T12:07:13Z
dc.date.available2018-07-27T12:07:13Z
dc.date.issued2017-12-01
dc.date.updated2018-07-24T11:53:28Z
dc.description.abstractThe Human Papillomavirus Prevention and Control Board brought together experts to discuss optimizing HPV vaccination and screening programs. Board members reviewed the safety profile of licensed HPV vaccines based on clinical and post-marketing data, reaching a consensus that current safety data is reassuring. Successful vaccination programs used well-coordinated communication campaigns, integrating (social) media to spread awareness. Communication of evidence supporting vaccine effectiveness had beneficial effects on the perception of the vaccine. However, anti-vaccination campaigns have threatened existing programs in many countries. Measurement and monitoring of HPV vaccine confidence over time could help understand the nature and scale of waning confidence, define issues and intervene appropriately using context-specific evidence-based strategies. Finally, a broad group of stakeholders, such as teachers, health care providers and the media should also be provided with accurate information and training to help support prevention efforts through enhanced understanding of the risks and benefits of vaccination. Similarly, while cervical cancer screening through population-based programs is highly effective, barriers to screening exist: awareness in countries with population-based screening programs, access for vulnerable populations, and access and affordability in low-and middle-income countries. Integration of primary and secondary prevention has the potential to accelerate the decrease in cervical cancer incidence.
dc.format.extent9 p.
dc.format.mimetypeapplication/pdf
dc.identifier.pmid29179869
dc.identifier.urihttps://hdl.handle.net/2445/124031
dc.language.isoeng
dc.publisherElsevier
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1016/j.pvr.2017.07.001
dc.relation.ispartofPapillomavirus Research, 2017, vol. 4, p. 45-53
dc.relation.urihttp://dx.doi.org/10.1016/j.pvr.2017.07.001
dc.rightscc by-nc-nd (c) Elsevier, 2017
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationVacuna del papil·lomavirus
dc.subject.otherPapillomavirus vaccines
dc.titleOvercoming barriers in HPV vaccination and screening programs
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
VorstersA.pdf
Mida:
211.25 KB
Format:
Adobe Portable Document Format